Dapagliflozin
An SGLT2 inhibitor that lowers blood sugar by blocking glucose reabsorption in the kidney, causing excess glucose to be excreted in urine, and has additional benefits for heart failure and chronic kidney disease regardless of diabetes status. It also promotes modest weight loss and blood pressure reduction.
Molekularmasse
408,8730 g/mol
LogP
2,30
TPSA
99,40 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCOc1ccc(Cc2cc([C@@H]3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)ccc2Cl)cc1
InChI
InChI=1S/C21H25ClO6/c1-2-27-15-6-3-12(4-7-15)9-14-10-13(5-8-16(14)22)21-20(26)19(25)18(24)17(11-23)28-21/h3-8,10,17-21,23-26H,2,9,11H2,1H3/t17-,18-,19+,20-,21+/m1/s1
Molecular Formula
C21H25ClO6
HBD / HBA
4 / 6
Rotierbare Bindungen
6
Schwere Atome
28
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
An SGLT2 inhibitor that lowers blood sugar by blocking glucose reabsorption in the kidney, causing excess glucose to be excreted in urine, and has additional benefits for heart failure and chronic kidney disease regardless of diabetes status. It also promotes modest weight loss and blood pressure reduction.
Selective SGLT2 inhibitor reducing renal glucose and sodium reabsorption.
Key pharmacokinetic parameters for Dapagliflozin: Half-life: 12.9 hours.
Yes, Dapagliflozin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL429910. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 9887712. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="dapagliflozin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/dapagliflozin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/dapagliflozin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/dapagliflozin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="dapagliflozin"></drugfyi-drug>